Harder Endpoints Needed In Studies Of Hepatic Encephalopathy Drugs Like Salix's Xifaxan, Advisory Committee Says
Future clinical trials of drugs for hepatic encephalopathy should be encouraged to seek hard endpoints, FDA's Gastrointestinal Drugs Advisory Committee suggested during its Feb. 23 review of Salix's Xifaxan (rifaximin)
You may also be interested in...
Salix's Xifaxan for hepatic encephalopathy passed advisory committee review, but members expressed unease about lingering safety concerns and called for additional studies.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials